May 31, 2026｜2026
ASCO 2026 | Henlius Accelerates Global Development of Its PD-L1 ADC, Demonstrating Promising Activity Across Multiple Difficult-to-Treat NSCLC Subgroups and Potential for Earlier-Line Development
HLX43 demonstrated encouraging antitumour activity in previously treated NSCLC patients regardless of histology or PD-L1 expression. This analysis included ex-China patients for the first time, with key efficacy endpoints assessed by blinded independent central review (BICR) and the first disclosure of progression-free survival (PFS) data.
In patients with EGFR wild-type nonsquamous NSCLC (nsqNSCLC), HLX43 achieved a confirmed objective response rate (cORR) of 36.8% and a median progression-free survival (mPFS) of 6.67 months. In patients with squamous NSCLC (sqNSCLC), cORR and mPFS reached 33.3% and 6.34 months, respectively. Among sqNSCLC patients previously treated with docetaxel, cORR further increased to 46.7%, with an mPFS of 6.90 months.
Based on the efficacy and manageable safety profile observed with HLX43 monotherapy, Henlius will continue to explore its potential in earlier-line treatment settings and evaluate its ability to deliver more durable clinical benefit for patients.
Shanghai, China, May 31, 2026 – Henlius (2696.HK) announced that key subgroup data from its core innovative asset, the PD-L1 antibody-drug conjugate (ADC) HLX43, in non-small cell lung cancer (NSCLC) were presented in a Rapid Oral Abstract Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation was based on a pooled analysis of NSCLC patients enrolled in the first-in-human Phase 1 study (HLX43-FIH101) and the global multicentre Phase 2 study (HLX43-NSCLC201), and included the first disclosure of long-term clinical benefit data, including progression-free survival (PFS). The results demonstrated that HLX43 monotherapy exhibited encouraging antitumour activity and a manageable safety profile in previously treated NSCLC patients. Notably, promising efficacy signals were observed in patient populations with limited treatment options, including those with EGFR wild-type nonsquamous NSCLC (nsqNSCLC) and squamous NSCLC (sqNSCLC) that had progressed following prior docetaxel treatment, providing important support for the continued clinical development of HLX43.
HLX43 is a potentially best-in-class and best-in-disease broad-spectrum antitumour ADC that combines immune checkpoint blockade with the cytotoxic activity of a topoisomerase inhibitor payload. By precisely conjugating a fully human IgG1 anti-PD-L1 antibody with an innovative linker-payload platform, HLX43 has demonstrated a favourable balance of antitumour activity and tolerability in clinical studies. At this year's ASCO Annual Meeting, data presented for HLX43 across NSCLC and nasopharyngeal carcinoma (NPC) further supported its potential as a biomarker-independent therapeutic option across multiple tumour types.
Reflecting the Challenges of Real-World Clinical Practice in Heavily Pretreated Patients
As of February 28, 2026, a total of 205 patients with advanced NSCLC had been enrolled in the study. Notably, ex-China patients were included in the analysis for the first time, further reflecting the continued advancement of HLX43’s global development programme. The study population comprised 95 patients with sqNSCLC and 110 patients with nsqNSCLC, including 63 patients with EGFR wild-type tumours and 47 patients with EGFR-mutant disease. Overall, the study population represented a heavily pretreated cohort with a substantial disease burden. Prior platinum-based chemotherapy had been administered in 99.0% of patients, while 82.0% had received prior immunotherapy, 41.0% had received targeted therapy, and 24.4% had previously been treated with docetaxel. Nearly 40% of patients had received three or more prior lines of therapy. Importantly, the vast majority of patients had undergone platinum-containing treatment regimens before receiving HLX43, reflecting prolonged treatment exposure and the cumulative toxicity and tolerability challenges commonly encountered in routine clinical practice. In addition, 27.8% of patients had bone metastases, 13.7% of patients had brain metastases and 13.7% had liver metastases, further demonstrating the complexity and disease burden of this real-world advanced NSCLC population.
Based on prior dose-escalation and dose-expansion findings, encouraging preliminary efficacy signals were observed with HLX43 at 2.0 mg/kg in patients with sqNSCLC and at 2.5 mg/kg in patients with nsqNSCLC. These dose levels were therefore selected as the recommended Phase 2/3 doses (RP2/3D) for the respective patient populations. To further evaluate the clinical benefit of HLX43 in patients with the greatest unmet need, this analysis focused on 68 key efficacy-evaluable patients treated at the RP2/3D levels and assessed by blinded independent central review (BICR), including 33 patients with sqNSCLC treated at 2.0 mg/kg and 35 patients with nsqNSCLC treated at 2.5 mg/kg. Among the nsqNSCLC cohort, 19 patients had EGFR wild-type tumors and 16 had EGFR-mutant disease, providing the basis for subsequent subgroup efficacy analyses.
Promising Activity Observed in Difficult-to-Treat Later-Line NSCLC Populations, Highlighting Broad Therapeutic Potential
Despite a heavily pretreated patient population—including patients who had failed multiple prior lines of therapy—and the use of the more stringent blinded independent central review (BICR) assessment, HLX43 continued to demonstrate encouraging antitumour activity, supporting its potential clinical value in later-line NSCLC treatment. Consistent and promising efficacy signals were observed across several clinically relevant subgroups:
Encouraging efficacy signals in EGFR wild-type nsqNSCLC: Among patients with EGFR wild-type nonsquamous NSCLC treated with HLX43 monotherapy at 2.5 mg/kg (n=19), the confirmed objective response rate (cORR) was 36.8%, the confirmed disease control rate (cDCR) was 94.7%, and the median progression-free survival (mPFS) was 6.67 months. Given the limited treatment options available for this patient population following prior immunotherapy and chemotherapy, these findings support the further development of HLX43 as a potential treatment option in EGFR wild-type nonsquamous NSCLC.
Antitumour activity maintained in sqNSCLC patients previously treated with docetaxel: In patients with sqNSCLC, cORR and mPFS reached 33.3% and 6.34 months, respectively; In patients with sqNSCLC who had previously failed docetaxel treatment and received third-line or later therapy (2.0 mg/kg, n=15), HLX43 monotherapy achieved a cORR of 46.7%, a cDCR of 80.0%, and an mPFS of 6.90 months. These results compare favourably with historically reported response rates for conventional chemotherapy in this setting and suggest that HLX43 may represent a potential treatment option for patients with heavily pretreated squamous NSCLC who have progressed following standard therapies.
Broad therapeutic potential independent of biomarker selection: Among patients with PD-L1-positive tumours (TPS ≥1%, n=29) and those with PD-L1-negative or unevaluable tumours (TPS <1% or NE, n=39), the cORRs were 37.9% and 33.3%, respectively, while the cDCRs reached 89.7% and 84.6%, respectively, with no meaningful difference observed between the two groups. Notably, the mPFS in the PD-L1-negative subgroup remained 5.49 months. These findings suggest that HLX43 may provide clinical benefit regardless of PD-L1 expression status, supporting its potential as a broadly applicable therapeutic approach and further expanding its potential utility across difficult-to-treat patient populations.
Manageable Monotherapy Safety Profile Supports Exploration in Earlier-Line Settings
As of February 28, 2026, a pooled analysis of 205 patients with NSCLC demonstrated that HLX43 exhibited an overall manageable safety profile. Treatment-related adverse events (TRAEs) were predominantly Grade 1–2, and no new safety signals were identified. Overall, 97.1% of patients experienced TRAEs, with Grade ≥3 TRAEs reported in 48.8% of patients. The most common Grade ≥3 TRAEs were decreased lymphocyte count (27.3%), anemia (14.1%), decreased white blood cell count (13.7%), and decreased neutrophil count (11.2%). The vast majority of adverse events were clinically manageable. Rates of TRAEs leading to treatment interruption, dose reduction, and treatment discontinuation were 38.0%, 12.2%, and 7.8%, respectively, while TRAEs leading to death occurred in 1.0% of patients.
Notably, across the 205-patient analysis population encompassing multiple dose levels, NSCLC subtypes, and treatment backgrounds, HLX43 demonstrated a consistent and manageable safety profile. While combination regimens remain the cornerstone of first-line NSCLC treatment, the ability of a therapeutic candidate to maintain favorable tolerability while delivering meaningful efficacy is a critical prerequisite for advancement into earlier treatment settings. As a PD-L1-targeting ADC, HLX43 combines targeted delivery with antitumour activity through a mechanism distinct from conventional immunotherapy-plus-chemotherapy approaches. The encouraging efficacy signals and manageable safety profile observed with HLX43 monotherapy in this study support further exploration of earlier-line treatment strategies, with the potential to optimize the patient treatment experience while maintaining efficacy and enabling more durable clinical benefit.
Accelerating Global Clinical Development and Unlocking the Full Potential of HLX43
As a cornerstone of Henlius' global development strategy for HLX43, the HLX43-NSCLC201 study is currently advancing across multiple countries and regions, including China, Europe, the United States, Japan, and Australia. Building on this foundation, Henlius continues to accelerate the global clinical development of HLX43. To date, approximately 1000 patients have been enrolled globally across HLX43 clinical studies, with NSCLC accounting for over 60% of the total enrollment (more than 500 patients). Beyond NSCLC, Henlius has initiated more than ten clinical studies evaluating HLX43 as monotherapy or in combination with other therapies across a broad range of solid tumours, including cervical cancer (CC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), metastatic colorectal cancer (mCRC), gastric/gastroesophageal junction (G/GEJ) cancer, pancreatic ductal adenocarcinoma (PDAC), and breast cancer (BC). Henlius continues to explore the therapeutic potential of HLX43 across multiple tumour types, with proof-of-concept data in CC, ESCC, NPC, and HNSCC having been presented or scheduled for presentation at major international congresses, including ESMO Asia, ASCO GI, ASCO, and ESMO. In addition to monotherapy development, Henlius is actively investigating combination strategies based on the immuno-oncology activity observed with HLX43. These include combinations with the Henlius’ proprietary anti-EGFR monoclonal antibody pimurutamab (HLX07) and anti-PD-1 monoclonal antibody serplulimab (trade name: Hetronifly® in Europe), among other therapeutic approaches. These efforts aim to further evaluate the potential of HLX43 in earlier-line treatment settings and across diverse combination strategies.
Looking ahead, Henlius will continue to advance the clinical development of HLX43 and other core innovative assets in lung cancer and multiple solid tumours. As additional efficacy, survival, and safety data become available, Henlius aims to further define the clinical positioning of HLX43 across different NSCLC subtypes, lines of therapy, and treatment combinations, with the goal of expanding treatment options for patients with advanced NSCLC who currently face limited therapeutic choices.
About HLX43-FIH101
This open-label, first-in-human Phase 1 study conducted in China was designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of HLX43 in patients with advanced or metastatic solid tumours. The study investigated dose levels ranging from 0.5 mg/kg to 4.0 mg/kg to determine the maximum tolerated dose (MTD), and further evaluated the efficacy of HLX43 at doses of 2.0–3.0 mg/kg in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who had progressed on or were refractory to standard therapies, with the aim of identifying the recommended Phase 2 dose (RP2D).
About HLX43-NSCLC201
This study is an open-label, international, multi-centre Phase 2 clinical trial aimed at evaluating the efficacy and safety of HLX43 in patients with advanced non-small cell lung cancer (NSCLC). The study consists of two phases: the first phase involves dose exploration to select the appropriate HLX43 dose for the second phase. The second phase is a single-arm, multi-centre Phase 2 clinical study. The primary objective of the study is to evaluate the clinical efficacy of HLX43 in advanced NSCLC. Secondary objectives include safety, tolerability, pharmacokinetic characteristics, immunogenicity, and the exploration of potential predictive or resistance biomarkers. The primary endpoint is the objective response rate (ORR) assessed by a Blinded Independent Central Review (BICR) committee according to RECIST v1.1 criteria.
Previous Chapter
Henlius' Pertuzumab Approved in China, Solidifying Breast Cancer Strategy as the First China-US-EU Approved Chinese Trastuzumab-Pertuzumab Combination
Next Chapter
Featured in Both The Lancet and ASCO: Henlius’ Serplulimab Pioneers a New Perioperative Chemotherapy-Sparring Regimen for Gastric Cancer
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy
Introduction
Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).
This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.
In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.
For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.
We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.
Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.
If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.
This Policy will help you understand:
I. How we collect your personal information
II. How we use your personal information
III. How we entrust, share, transfer and publicly disclose your personal information
IV. Cross border transfer of personal information
V. How we store your personal information
VI. Security measures
VII. Your rights
VIII. Personal information of minors
IX. Updates to this Policy
X. How to contact us
I. How do we collect your personal information?
In addition to our employees, we may process personal information of the following persons:
• Visitors and users of our website;
• Healthcare Professionals;
• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;
• Subjects of clinical trials and their relatives;
• Consumers/patients and their relatives using our products or services;
• Staff of business partners (including vendors, distributors, partners, etc.); and
• Our applicants.
We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.
Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:
• Your personal information provided to us voluntarily
When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.
• Personal information collected by us independently through our website and other online channels
When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.
• Personal information we collect from vendors or business partners
In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.
• Personal information we collect from publicly available sources
We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.
Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.
II. How do we use your personal information?
We may use your personal information for the following purposes:
• Operating, maintaining and improving our website and other online resource;
• Researching, developing, providing and continuously improving our products and services;
• Conducting and managing daily business;
• Academic interaction with healthcare professionals;
• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;
• Providing subscription services for our news, announcements, or investor-related updates;
• Managing and maintaining our relationship and communications with business contacts who reach us through our website;
• Recruiting and human resource management;
• Internal compliance management，audit，record-keeping; and
• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..
We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.
III. How do we entrust, share, transfer and publicly disclose your personal information?
1. Entrustment
We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.
2. Sharing and public disclosure
For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:
• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;
• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and
• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.
• other circumstances permitted by applicable PRC laws and regulations.
If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.
3. Transfer
We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.
IV.How do we provide your personal information across borders?
In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.
You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.
V. How do we store your personal information?
We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:
• Applicable laws, regulations and other relevant requirements;
• The period of time needed for us to provide services, maintain business relations or interact with you; and
• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.
VI. What security measures do we take to protect your personal information?
In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.
VII. Your rights
In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:
• To know about and make decisions regarding the processing of your personal information;
• To access or copy your personal information;
• To correct or supplement your personal information;
• To delete your personal information;
• To request for explanation of rules regarding processing of personal information; and
• To change the scope of your consent or revoke your consent , where processing is based on your consent.
If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.
VIII. How do we process the personal information of minors?
For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.
If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.
IX. Updates of the Policy
We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.
Last updated: March 30, 2026.
X. How to contact us?
If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:
Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai
Tel.: 021- 33395800
Postal Code: 200233
Email: PR@tmwjjd.com
Cookies Policy
When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.
Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.
You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.
For more information about how we process personal information, please refer to our Privacy Notice.
Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.
Accessibility
Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.
We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.
If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.
Contact us:
Email: PR@tmwjjd.com
(Please include “Website Accessibility” in the subject line)
Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.
Terms of Use
This website (http://www.tmwjjd.com/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.
Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.
Prohibited Conduct:
You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.
Copyright
All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.
Disclaimers
To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.
You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.
Medical Information
Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.
Third Party Websites
This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.
Privacy
Henlius respects your privacy. Please refer to our Privacy Notice for details.
Governing Law
These Terms of Use shall be governed by the laws of the People’s Republic of China.
Last updated: March 30, 2026